The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Cosentyx (secukinumab) on April 17, 2026. This approval was for an efficacy supplement, indicating new data supporting the drug's effectiveness.
What this means
This supplemental approval for Cosentyx (secukinumab) based on efficacy data signifies that the FDA has evaluated new clinical evidence. While specific trial details are not provided in this announcement, the approval indicates that the agency found sufficient data to support the drug's effectiveness for an expanded use or patient population. This expands the therapeutic options for clinicians and patients.
Source
The information regarding this supplemental approval for Cosentyx (secukinumab) was sourced from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 125504 S-98, was granted on April 17, 2026, and is publicly accessible on accessdata.fda.gov.